# Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

> **NCT05319639** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 51 (estimated)

## Conditions studied

- Gastric Cancer Stage IV

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Levo-Leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** Paclitaxel
- **DRUG:** Irinotecan
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT05319639
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-16
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05319639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05319639, "Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05319639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*